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Abstract
The natural history of KPC-producing Klebsiella pneumoniae (KPC KP) carriage is unknown. We aimed to examine the duration of KPC KP
carriage following hospital discharge and to study the risk factors for persistent carriage. A cohort of 125 KPC KP carriers was followed
monthly for between 3 and 6 months after discharge from an acute-care hospital. Rectal swabs and data were collected at baseline and at
each visit. KPC KP was detected by culture and direct blaKPC PCR. Acquisition time was regarded as the earliest date of KPC KP isolation.
Resolution of carriage was deﬁned as a negative KPC KP test in at least two consecutive samples. Analyses were separated for recent
(<4 months) (REC, 75 patients) and remote ( 4 months) (REM, 50 patients) acquisition groups. Risk factors for persistent carriage were
examined by survival analyses for the REC group and by prevalence methods for the REM group. The mean age of patients was 67.5 years
and 49.6% were male. Forty-six (61%) patients in the REC group and 14 (28%) in the REM group were persistent carriers (p < 0.001). A
signiﬁcant risk factor for persistent carriage identiﬁed in both the REC and REM groups was the presence of any catheter (p < 0.05). Unique
risk factor groups included long-term care facility (LTCF) residence (p < 0.01) and a low functional status as measured by the Barthel’s
index (p < 0.05) in the REC group and high Charlson’s score in the REM group (p < 0.05). Out of the entire 100 patients who had at least
one negative sample, only 65 remained negative on subsequent cultures. In conclusion, persistent carriage of KPC KP is associated with
catheter use and a low functional status; it is more common in patients with recent acquisition and is related to LTCF stay. A single negative
KPC KP test is insufﬁcient to exclude persistent carriage.
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Introduction
The ﬁrst cases of Klebsiella pneumoniae carbapenemase
(KPC)-Klebsiella pneumoniae were reported from the mid-
Atlantic region of the United States between 1997 and 2000
[1–3]. Since then, KPC-producing K. pneumoniae (KPC KP)
have spread and become endemic in several countries in
Europe, the Middle East, Asia and South America [4,5]. This
epidemic is caused by a predominantly monoclonal dissem-
ination of the Sequence-Type (ST)-258 and its Clonal
Complex (CC) [6–8], which is still by far the dominant
clone in Israel [9].
Carriage of KPC KP in the gastrointestinal tract is important
for several reasons. First, it may precede and possibly serve as
a source for subsequent clinical infection in approximately 9%
of carriers [10,11]. Second, carriers may serve as an important
reservoir for dissemination of KPC KP in healthcare facilities
[12–14]. Consequently, active surveillance for carriage of KPC
KP and other carbapenem-resistant Enterobacteriaceae (CRE)
has become an integral part of local and national programmes
designed to control the spread of CRE in the healthcare setting
[14–17].
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Very little is known about the duration of carriage of KPC
KP and of the risk factors associated with persistent carriage.
We have recently published a study on a cohort of 59 known
CRE carriers and found that 23 of them (38%) were positive at
their subsequent hospital admission [18]. Persistent carriers
were more likely to be admitted from another healthcare
facility, had a higher rate of recent antibiotic exposure and had
a shorter duration of time from ﬁrst detection of CRE to
admission [18]. This study sampled patients at their second
hospital admission and therefore did not examine the overall
natural history of CRE carriage.
In the current study, we followed systematically a cohort of
previously known KPC KP carriers following their hospital
discharge. Our aims were (i) to examine the duration of
carriage of KPC KP and (ii) to study the risk factors for
persistent carriage.
Methods
Setting, patient selection and collection of surveillance
specimens
The study was conducted at the Tel Aviv Sourasky Medical
Center (TASMC), a 1200-bed tertiary care hospital, and at the
Reut Hospital, a 300-bed long-term care facility (LTCF), both
in Tel Aviv, Israel. In this prospective, observational, cohort
study, previously known carriers of KPC KP were identiﬁed
using the computerized database of the TASMC and the
National registry of KPC-KP carriers [17]. Patients were asked
to enroll and provide a written informed consent. Patients
who were unable to give an informed consent (e.g. critically ill
patients) were not approached. Surveillance KPC KP rectal
cultures were collected as previously described [19] at ﬁve
time-points: before discharge, and at 2 weeks, 1, 2 and 3
months following hospital discharge (Fig. S1). A selected group
of persistently KPC KP positive patients (positive on their 4 or
5th tests) was sampled also at a sixth time period. Data were
collected at enrollment and at each time-point by a patient’s
enrollment form that included demographics, exposures to
antibiotics, underlying conditions and invasive devices, as well
as the Barthel’s (ADL) index [20] and the Charlson’s co-
morbidities score [21], and a follow-up form that included
questions regarding recent (<1 month) use of an invasive
device or antibiotics and LTCF residence. The study was
approved by the institutional ethical committee.
Microbiological and molecular methods
A nylon ﬂocked swab system with liquid Amies medium
(eSwab; Copan, Brescia, Italy) was used for rectal sampling, and
was immediately transferred to the laboratory and processed.
Swabs were streaked onto CHROMagar-KPC Plates (HyLabs,
Rehovot, Israel) and into a 3-mL Brain-Heart Infusion (BHI)
broth tube and were incubated overnight at 36°C. CRE
suspicious colonies were identiﬁed and processed, including a
blaKPC-PCR, as previously described [19], with the exception
that a manual biochemical kit (Enterotest; HyLabs) was used
for species identiﬁcation. In addition, blaKPC-PCR was per-
formed from the BHI broth [22].
Data analysis
Clearance of KPC KP carriage was deﬁned as at least two
consecutive negative cultures and blaKPC-PCR tests without
any subsequent positive test in accordance with the Israeli
National Guidelines [23]. The time to clearance was deter-
mined as the time from ﬁrst detection of KPC KP until ﬁrst
negative KPC KP test of the two consecutive negative tests.
For the analyses, patients were divided into two groups,
according to the time from ﬁrst identiﬁcation of KPC KP, by
either surveillance or clinical cultures, to the time of hospital
discharge: acquisition of KPC KP at less or more than
4 months from discharge was considered recent (REC) or
remote (REM), respectively (see Fig. 1). This division was
undertaken as survival analysis was deemed inappropriate for
the patients with remote acquisition. Associations between
REC/REM groups and other baseline demographic and clinical
variables were evaluated with analysis of variance, Kruskal–
Wallis or chi-squared tests. In the REC group, the association
between the baseline demographic and clinical variables and
time to KPC KP clearance is presented as Kaplan–Meier
curves and compared using the Log Rank test. Cox propor-
tional hazards models were constructed to evaluate the
adjusted effects as hazard ratios (HRs) and 95% conﬁdence
intervals (CIs). Variables with p value of < 0.1 in the univariate
FIG. 1. Time interval from initial detection of KPC-producing
Klebsiella pneumoniae (KPC KP) to enrollment. The 4-month time-
point is marked by an arrow.
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analysis entered the multivariate model. In addition, variables
that were considered to be critical factors (age, log of the time
from ﬁrst KPC KP detection to enrollment and recent use of
antibiotics) were also added. Use of an invasive device, use of
antibiotics and LTCF residence were treated as time-depen-
dent variables.
In the REM group, the association between the baseline
demographic and clinical variables and KPC KP clearance was
compared using similar methods to those described for REC/
REM group comparisons. Multivariate analysis was constructed
with similar criteria to those described above, using a binary
logistic regression model. The 95% CI for the HR of the
Charlson’s score was incalculable due to the low number
(n = 1) of the reference group.
Results
Patients’ and isolates’ characteristics
The study was conducted from December 2008 through to
January 2011, enrolling 125 patients with previous identiﬁca-
tion of KPC-KP 1. All patients that were approached had
agreed to participate in the study and had completed the initial
sampling and data collection. Of these, 83 have completed the
ﬁve follow-up tests and 42 patients did not: 28 have died and
14 have dropped out. An additional sixth test was performed
in 30 persistently positive patients. The time intervals between
ﬁrst detection of KPC KP and enrollment are presented in
Fig. 1. Accordingly, 75 and 50 patients were included in the
REC and REM groups, respectively. The clinical and
demographic characteristics of these patients are presented
in Table 1. Compared with the REM group, patients in the REC
group had a higher rate of positive KPC KP test at enrollment
(71 vs. 20%, p < 0.001), higher rate of antibiotic treatment in
the preceding month (80% vs. 56%, p < 0.01), higher rate of
LCTF discharge (70.7 vs. 51%, p < 0.05) and a higher post-
discharge mortality rate (32 vs. 12%, p = 0.01). Patients in the
REC group tended to have an overall higher Charlson’s score,
but the difference was not statistically signiﬁcant (p = 0.08). In
addition to KPC KP, KPC-producing E. coli was isolated in ﬁve
samples, taken from four patients.
Duration of KPC KP carriage following hospital discharge
Overall, 544 rectal samples were collected, of which 225 (41%)
were positive. The percentages of KPC KP positive tests as a
function of the time from ﬁrst detection of KPC KP and
sampling schedule are presented in Fig. 2. The percentage of
positive results declined with increased time from ﬁrst KPC
KP detection (Fig. 2a). The percentage of positive results also
declined from the ﬁrst (enrollment) test up to the ﬁfth
(3 months) test (Fig. 2b). The sixth sample was taken from 30
persistent carriers (median time from the ﬁfth sampling,
61 days; interquartile range (IQR), 38–63); 21 tests (70%)
were found to be positive.
Overall, resolution of carriage (e.g. two consecutive nega-
tive tests with no subsequent positive test) was documented
for 65/125 (52%). Resolution of carriage was documented in
29/75 (39%) and 36/50 (72%) of the REC and REM patients,
respectively (p < 0.001). The rates of resolution were similar
in the 83 patients that had completed the ﬁve-point follow-up:
21/45 (46%) and 30/38 (79%) in the REC and REM patients,
respectively. To evaluate the validity of this criterion, we
examined the number of patients who fulﬁlled it but subse-
quently had positive testing and compared it to using one or
three consecutive negative tests as criteria (Table 2). Overall,
KPC KP clearance was correctly deﬁned (e.g. no subsequent
positive test) at higher rates in the REM group than in the REC
group; the rates increased with increased number of negative
TABLE 1. Demographic and clinical characteristics of
patients at enrollment
Variable
REC
groupa
(n = 75)
REM
groupb
(n = 50) p-value
Male (%) 36 (48.0) 26 (52.0) 0.661
Mean age (SD) 69.8 (18.0) 64.2 (20.9) 0.099
Median time (days) from KPC KPc
identiﬁcation to enrollment (25–
75% interval)
26 (11–46) 419 (333–662) p < 0.001
Negative KPC KP test at
enrollment (%)
22 (29.3) 40 (80.0) <0.001
ADLd (Barthel’s) index, no. (%)
0–5 35 (46.6) 22 (44.0) 0.958
5–50 20 (26.7) 14 (28.0)
>50 20 (26.7) 14 (28.0)
Charlson’s score, no. (%)
0 (%) 11 (14.7) 15 (30.0) 0.080
1–5 (%) 40 (53.3) 25 (50.0)
>5 (%) 24 (32.0) 10 (20.0)
Invasive device present (%) 45 (60.0) 27 (55.1) 0.589
Surgical procedure in the
last year (%)
35 (46.7) 19 (38.0) 0.338
Admission from an LTCFe (%) 41 (54.7) 21 (42.0) 0.165
Carriage of resistant bacteriaf(%) 12 (16.0) 9 (18.0) 0.770
Antibiotic treatment during the
month before enrollment (%)
60 (80.0) 28 (56.0) 0.004
Speciﬁc antibiotic during the month before enrollment
Penicillin (%) 19 (25.7) 8 (16.0) 0.200
b-lactams/b-lactamase inhibitors 3 (4.1) 3 (6.1) 0.614
Cephalosporin (%) 27 (37.0) 11 (22.4) 0.089
Carbapenem (%) 11 (15.1) 3 (6.1) 0.129
Quinolones (%) 10 (13.7) 7 (14.3) 0.927
Aminoglycosides (%) 13 (17.8) 8 (16.3) 0.832
Metronidazole (%) 10 (13.7) 4 (8.2) 0.347
Macrolides (%) 10 (13.7) 2 (4.1) 0.121
Median duration of hospitalization,
days (25–75% interval)
19 (7–44) 11 (7-218) 0.780
Discharge to an LTCFe (%) 53 (70.7) 25 (51.0) 0.027
Early drop-out (%) 11 (14.7) 6 (12.0) 0.670
Deceased (%) 25 (33.3) 6 (12.0) 0.007
aREC, the recent KPC KP acquisition group (<4 months prior to enrollment).
bREM, the remote KPC KP acquisition group (more than 4 months prior to
enrollment).
cKPC KP, KPC-producing Klebsiella pneumoniae.
dADL, activities of daily living index.
eLTCF, long-term care facility.
fResistent bacteria, including methicillin-resistant Staphylococcus aureus, vancomy-
cin-resistant enterococci and carbapenem-resistant Acinetobacter baumannii.
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tests, although the number of patients available for the analysis
had declined.
Risk factors for persistent KPC KP carriage following recent
acquisition
The rate of persistent KPC KP carriage was studied in the REC
group and included all the variables detailed in Table 1 by
survival analysis. Signiﬁcant risk factors at enrollment included
low ADL (Barthel’s) index, the presence of an invasive device,
admission from an LCTF and discharge to an LTCF (Fig. 3).
Recent use of antimicrobials, either at enrollment or during
the follow-up period, was not associated with persistent
carriage. In all of these variables, persistence of KPC KP
carriage at the end of the follow-up was found in c. 50% of
patients with the unfavourable characteristics, compared with
c. 20% of patients with the favourable characteristics. The ADL
index correlated signiﬁcantly with the place of residence and
the presence of an invasive device. A multivariate analysis that
included the signiﬁcant variables from the unadjusted analysis
as well as the three critical variables (see in ‘Methods’) was
constructed. Taken apart, the ADL index, LTCF residence and
the presence of an invasive device were identiﬁed as signiﬁcant
risk factors (Table S1a–c). However, none of these variables
remained statistically signiﬁcant in the joint model, as a result
of signiﬁcant correlation between the variables (data not
shown).
Risk factors for persistent KPC KP carriage following remote
acquisition
The rate of persistent KPC KP carriage was studied in the REM
group and included all the variables detailed in Table 1.
Persistent carriers (n = 14) weremore likely to have an invasive
device at enrollment (10/14 (76.9%) vs. 17/36 (47.2%),
p = 0.065). Persistent carriers had a higher Charlson’s score
comparedwith non-carriers: score 0–1 (7%) vs. 14 (39%), scores
1 to 5–9 (64%) vs. 16 (44%) and scores higher than 5–4 (29%) vs.
6 (17%) (p = 0.087). Interestingly, persistent carriers were less
likely to have a surgical procedure in the preceding year (2/14
(14%) vs. 17/36 (47.2%), p = 0.031). In multivariate analysis, the
presence of an invasive device (HR = 7.69, 95% CI, 1.03–50;
p = 0.046) and high Charlson’s score (HR = 111.11 and 200 for
scores of 1–5 and >5 compared with 0, respectively; p < 0.05;
the 95% CI was incalculable due to the small reference value)
were identiﬁed as independent risk factors.
Discussion
Very little is known about the duration of and the risk factors
for persistent gastrointestinal carriage of KPC KP, as well as
(a)
(b)
FIG. 2. The rates of KPC-producing Klebsiella pneumoniae (KPC KP)-
positive samples. (a) The rates of KPC KP-positive samples according
to the time from initial identiﬁcation of KPC KP. (b) The rates of KPC
KP-positive samples according to the sampling schedule. The numbers
of patients are indicated inside the bars. The time of the sixth test
reﬂects the median time interval.
TABLE 2. Validity of different criteria for deﬁning clearance
of KPC KP carriage
Criteriaa
Study
group
Total number
of patients, n
Patients with
negative tests, n
Patients with
KPC KPb
clearance, n (%c)
1  2 tests  1 negative test
RECd 69 54 29 (54)
REMe 49 43 36 (84)
2  3 tests  2 negative tests
REC 55 31 25 (81)
REM 42 36 32 (89)
3  4 tests  3 negative tests
REC 52 19 16 (84)
REM 39 31 29 (94)
aCriteria, number of consecutive negative tests (without subsequent positive test)
necessary for deﬁning clearance of KPC KP carriage.
bKPC KP, KPC-producing Klebsiella pneumoniae.
c%, ratio of the number of patients with KPC KP clearance to the number of
patients with negative tests.
dREC, recent (<4 months) KPC KP acquisition group.
eREM, remote (>4 months) KPC KP acquisition group.
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other types of resistant gut bacteria, in non-hospitalized
patients. In the present study, a cohort of previously known
KPC KP carriers was followed-up by serial rectal cultures for
3 months after hospital discharge. We found that the rate of
positivity is highest (74%) when the test is carried out within
30 days of ﬁrst KPC KP isolation, but declines to <30% once
the time interval is over 6 months (Fig. 2b). Accordingly,
patients with remote acquisition of KPC KP were less likely to
remain positive in subsequent samplings, as was also reported
by Schechner [18] and Ben-David [24]. These patients also had
lower Charlson’s score, had a lower mortality rate and were
more likely to be discharged to their homes. The difference in
the rates of persistent carriage at the time of enrollment
between the two acquisition groups, is probably a reﬂection of
the fact that patients that had survived long enough following
the initial KPC KP acquisition, are healthier in general and thus
less likely to be exposed to the various risk factors for
persistent carriage.
Hypothetically, repeated positive KPC KP testing may result
from either persistent carriage in the individual patient or from
reacquisition from other patients. The latter is especially of
great concern in Israel, as our national policy is to group
previously known carriers in a single ward [17]. A supporting
ﬁnding for the role of reacquisition, is the association between
residence at an LTCF and persistence carriage in the REC
group, which was also reported by Schechner et al. [18]. The
average prevalence of KPC KP carriage in the major LTCFs in
Israel was reported to be 17% [24], much higher than the
prevalence reported in two general hospitals in Israel even at
the peak of the KPC KP epidemic [13,25]. New acquisition of
KPC KP was detected in 12% of LTCF patients, and was
especially common in institutions with high prevalence of KPC
KP carriage or in patients that shared a room with a known
carrier [24]. Hence, it is likely that even following resolution of
carriage in an individual patient, patients may still get re-
infected during their subsequent admission, especially if they
are admitted to an LTCF with a high prevalence of KPC KP
carriage.
Low functional status (ADL index), high co-morbidity index
(Charlson’s score) and the presence of an invasive device
were identiﬁed as risk factors in the REC group, the REM
group and in both groups, respectively. These factors were
not identiﬁed as risk factors for persistent carriage by
Schechner et al. [18], but they were identiﬁed as risk factors
(a) (b)
(c) (d)
FIG. 3. Risk factors for persistent carriage of KPC-producing Klebsiella pneumoniae (KPC KP) in the recent acquisition (<4 months) group (n = 75).
Kaplan–Meier estimates for cumulative survival function for clearance of KPC KP. (a) The Barthel’s (ADL) index (presented here in three categories);
(b) the presence of an invasive device; (c) pre-admission residence (home vs. long-term care facility (LTCF)); (d) discharge destination (home vs.
LTCF).
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for KPC KP acquisition [13,26]. Although ADL and an invasive
device were correlated with residence in an LTCF in the REC
group, their association with persistent KPC KP carriage is
not entirely clear, as residence in an LTCF was not identiﬁed
as a risk factor in the REM group. This suggests that patients
with poor functional status and co-morbidity conditions are
more likely to remain colonized by hospital-acquired organ-
isms, such as KPC KP.
An intriguing difference between our study and previous
reports [18,24] is the lack of association between persistent
carriage and recent antibiotic therapy. This was also reported in
a study that looked into the duration and risk factors for
persistent carriage of ESBL-producing Enterobacteriaceae [27].
A likely explanation is the very high rate of recent antibiotic
therapy in all of our patients, especially in the REC group (80%).
Accurate and reliable determination of resolution of
carriage is important for both the individual patient and the
medical institution, especially when a policy of carriers
cohorting is implemented. Our ﬁndings indicate that a single
negative test cannot serve as a reliable indication for resolu-
tion, as only 65 patients out of 97 with two tests (67%) did not
have a subsequent positive test. This rate increased with
increased number of negative tests and in patients with remote
acquisition. The total number of tests and the duration of
follow-up in our study are not sufﬁcient to determine the
exact number of tests that are required for deﬁning KPC KP
clearance. However, our risk factor analyses can indicate
patients that are less likely to remain carriers (e.g. patients
admitted from home, with good functional status and with
remote acquisition, in whom testing for resolution of carriage
is likely to be beneﬁcial).
Our study has several limitations. First, we were unable to
distinguish between persistence of carriage and re-infection.
In theory, the use of a molecular epidemiology tool might
have allowed us to answer this question. However, due to
the predominantly monoclonal nature of the KPC KP
epidemic in Israel (as shown in our recent report [9]), such
a distinction would have been impossible in the vast majority
of patients. Also, the distinction between persistence and re-
acquisition is further complicated by the fact that the KPC
gene may be transmitted in-situ by the transfer of mobile
genetic elements from one strain to another strain or a
different species altogether [28,29]. Thus, even the isolation
of a different species of KPC-producing Enterobacteriaceae,
as was found in four patients, may not provide a deﬁnite
proof of re-acquisition.
Second, there might have been a selection bias toward
relatively healthier patients, as patients who were unable to
give an informed consent (e.g. critically ill patients) were not
approached.
Third, there might have been a selection bias in the REM
group, toward the selection of relatively sicker patients, as
patients with remote acquisition that were healthier were less
likely to be admitted and thus were not recruited. It is
noteworthy that even with this potential bias, this group was
basically healthier than the REC group (Table 1) and had a
higher rate of KPC KP clearance.
In conclusion, our study shows that although resolution of
carriage occurs in the majority of patients with remote
acquisition, it is uncommon in patients with recent acquisition,
especially those with poor functional status who reside in an
LTCF. Repeat KPC KP testing in this population is likely to be
futile or misleading.
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